Dermatology News and Research

Latest Dermatology News and Research

Impaired immunological memory causes psoriasis, atopic eczema

Scientists from the Centre for Allergy and Environment in Munich (ZAUM), the Helmholtz Zentrum München and the Technische Universität München have reached a milestone in their specialist area with their discovery of the causes of atopic eczema and psoriasis.

22 Jul 2011

FDA approves Merz Aesthetics' XEOMIN for temporary improvement of glabellar lines

Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Experts to explore wound healing abilities of dolphins

A Georgetown University Medical Center (GUMC) scientist who has previously discovered antimicrobial compounds in the skin of frogs and in the dogfish shark has now turned his attention to the remarkable wound healing abilities of dolphins.

21 Jul 2011

Caltech, Zcube collaboration will bring painless transdermal drug delivery to patients

Zcube Srl, a research venture of the Italian pharmaceutical company Zambon, and the California Institute of Technology (Caltech) have signed an exclusive research and option agreement to develop and commercialize skin patches that contain embedded carbon nanotubes for delivering drugs. The patches will first be developed to painlessly administer drugs through the skin; other applications are envisioned for future use. Mory Gharib, Hans W. Liepmann Professor of Aeronautics and professor of bioinspired engineering, is the principal investigator at Caltech.

21 Jul 2011

Receptor GPR56 could have a critical role in cancer progression

Melanoma is devastating on many fronts: rates are rising dramatically among young people, it is deadly if not caught early, and from a biological standpoint, the disease tends to adapt to even the most modern therapies, known as VEGF inhibitors.

21 Jul 2011

Valeant, sanofi-aventis partner to market and distribute Zuacta cream

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL, has entered into an agreement with sanofi-aventis Canada Inc.

20 Jul 2011

Graceway receives FDA approval for Zyclara Cream to treat actinic keratoses

Graceway Pharmaceuticals, LLC announced today that the Food and Drug Administration (FDA) has approved Zyclara Cream, 2.5% for the treatment of actinic keratoses, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses.

19 Jul 2011

Upsher-Smith initiates USL261 ARTEMIS1 Phase III study for seizure clusters in epilepsy patients

Upsher-Smith Laboratories, Inc. announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of USL261, an investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, frequently referred to as seizure clusters. USL261 has been granted orphan drug designation for this use by the Food and Drug Administration (FDA).

18 Jul 2011

Positive results from levomilnacipran Phase III study for major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of adults with major depressive disorder (MDD).

18 Jul 2011

Valeant to acquire Ortho Dermatologics

Valeant Pharmaceuticals International, Inc. announced today that Valeant's subsidiaries, Valeant Pharmaceuticals North America LLC (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc.

16 Jul 2011

Yervoy, a new melanoma drug approved in Australia

Australia has approved the world’s first drug to prolong the lives of people with advanced melanoma. The drug Yervoy received the nod from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the deadliest form of skin cancer but for whom other treatments have failed.

14 Jul 2011

Two Canadian dermatologists receive prestigious awards at CDA conference

The Canadian Dermatology Association is happy to announce the winners of its most prestigious awards as presented at the President's gala during the CDA 86th Annual Conference in Edmonton.

14 Jul 2011

Specific miRNAs play a key role in melanoma metastasis

Researchers at the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, identified for the first time the key role specific microRNAs play in melanoma metastasis to simultaneously cause cancer cells to invade and immunosuppress the human body's ability to fight abnormal cells.

12 Jul 2011

Ivermectin cream demonstrates activity against head lice eggs

In a study sponsored by Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, scientists from the University of Massachusetts, Amherst presented data showing that a 0.5% ivermectin (IVM) cream formulation was active against lice eggs from permethrin resistant head lice.

11 Jul 2011

New corticosteroid with cream-like base

Upsher-Smith Laboratories, Inc. announced the launch of Trianex 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment.

11 Jul 2011

Sanofi announces strategic divestiture of dermatology business to Valeant

Sanofi announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc., for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.

11 Jul 2011

Valeant signs agreement to acquire Dermik

Valeant Pharmaceuticals International, Inc. announced today that Valeant and its subsidiary, Valeant International SRL, have signed an agreement to acquire Dermik, a dermatology unit of Sanofi in the U.S. and Canada, as well as the worldwide rights to Sculptra Aesthetic.

11 Jul 2011

Top-line results from HyQ subcutaneous IG phase III study in patients with primary immunodeficiency

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use in patients with primary immunodeficiency (PI).

From Baxter International Inc. 8 Jul 2011

Brigham and Women's Hospital receives NIH Program of Excellence in Glycosciences award

The laboratory of Robert Sackstein, MD, PhD, of the Dermatology Department at Brigham and Women's Hospital (BWH), has been granted a prestigious Program of Excellence Award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), to support investigations in glycobiology: the discipline which studies how sugars direct biologic processes.

8 Jul 2011